Trial Profile
A Prospective , Cohort, Real World Study Analyzing Antibody Responses Among Five Different Sars-Cov-2 Vaccines in Chronic Myeloid Leukemia Patients
Status:
Completed
Phase of Trial:
Phase IV
Latest Information Update: 31 Jul 2023
Price :
$35
*
At a glance
- Drugs Ad26.COV2 S (Primary) ; AZD 1222 (Primary) ; Elasomeran (Primary) ; SARS-COV-2 vaccine-inactivated-Sinovac-Biotech (Primary) ; Tozinameran (Primary)
- Indications Chronic myeloid leukaemia
- Focus Pharmacodynamics
- 31 Jul 2023 New trial record
- 15 Jun 2023 Results presented at the 28th Congress of the European Haematology Association